Cargando…

Revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of γ-actinorhodin

Of the thousands of natural product antibiotics discovered to date, only a handful have been developed for the treatment of bacterial infection. The clinically unexploited majority likely include compounds with untapped potential as antibacterial drugs, and in view of the ever-growing unmet medical...

Descripción completa

Detalles Bibliográficos
Autores principales: Nass, Nada M., Farooque, Sannia, Hind, Charlotte, Wand, Matthew E., Randall, Christopher P., Sutton, J. Mark, Seipke, Ryan F., Rayner, Christopher M., O’Neill, Alex J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727142/
https://www.ncbi.nlm.nih.gov/pubmed/29234001
http://dx.doi.org/10.1038/s41598-017-17232-1
_version_ 1783285814745104384
author Nass, Nada M.
Farooque, Sannia
Hind, Charlotte
Wand, Matthew E.
Randall, Christopher P.
Sutton, J. Mark
Seipke, Ryan F.
Rayner, Christopher M.
O’Neill, Alex J.
author_facet Nass, Nada M.
Farooque, Sannia
Hind, Charlotte
Wand, Matthew E.
Randall, Christopher P.
Sutton, J. Mark
Seipke, Ryan F.
Rayner, Christopher M.
O’Neill, Alex J.
author_sort Nass, Nada M.
collection PubMed
description Of the thousands of natural product antibiotics discovered to date, only a handful have been developed for the treatment of bacterial infection. The clinically unexploited majority likely include compounds with untapped potential as antibacterial drugs, and in view of the ever-growing unmet medical need for such agents, warrant systematic re-evaluation. Here we revisit the actinorhodins, a class that was first reported 70 years ago, but which remains poorly characterized. We show that γ-actinorhodin possesses many of the requisite properties of an antibacterial drug, displaying potent and selective bactericidal activity against key Gram-positive pathogens (including Staphylococcus aureus and enterococci), a mode of action distinct from that of other agents in clinical use, an extremely low potential for the development of resistance, and a degree of in vivo efficacy in an invertebrate model of infection. Our findings underscore the utility of revisiting unexploited antibiotics as a source of novel antibacterial drug candidates.
format Online
Article
Text
id pubmed-5727142
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-57271422017-12-13 Revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of γ-actinorhodin Nass, Nada M. Farooque, Sannia Hind, Charlotte Wand, Matthew E. Randall, Christopher P. Sutton, J. Mark Seipke, Ryan F. Rayner, Christopher M. O’Neill, Alex J. Sci Rep Article Of the thousands of natural product antibiotics discovered to date, only a handful have been developed for the treatment of bacterial infection. The clinically unexploited majority likely include compounds with untapped potential as antibacterial drugs, and in view of the ever-growing unmet medical need for such agents, warrant systematic re-evaluation. Here we revisit the actinorhodins, a class that was first reported 70 years ago, but which remains poorly characterized. We show that γ-actinorhodin possesses many of the requisite properties of an antibacterial drug, displaying potent and selective bactericidal activity against key Gram-positive pathogens (including Staphylococcus aureus and enterococci), a mode of action distinct from that of other agents in clinical use, an extremely low potential for the development of resistance, and a degree of in vivo efficacy in an invertebrate model of infection. Our findings underscore the utility of revisiting unexploited antibiotics as a source of novel antibacterial drug candidates. Nature Publishing Group UK 2017-12-12 /pmc/articles/PMC5727142/ /pubmed/29234001 http://dx.doi.org/10.1038/s41598-017-17232-1 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Nass, Nada M.
Farooque, Sannia
Hind, Charlotte
Wand, Matthew E.
Randall, Christopher P.
Sutton, J. Mark
Seipke, Ryan F.
Rayner, Christopher M.
O’Neill, Alex J.
Revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of γ-actinorhodin
title Revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of γ-actinorhodin
title_full Revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of γ-actinorhodin
title_fullStr Revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of γ-actinorhodin
title_full_unstemmed Revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of γ-actinorhodin
title_short Revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of γ-actinorhodin
title_sort revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of γ-actinorhodin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727142/
https://www.ncbi.nlm.nih.gov/pubmed/29234001
http://dx.doi.org/10.1038/s41598-017-17232-1
work_keys_str_mv AT nassnadam revisitingunexploitedantibioticsinsearchofnewantibacterialdrugcandidatesthecaseofgactinorhodin
AT farooquesannia revisitingunexploitedantibioticsinsearchofnewantibacterialdrugcandidatesthecaseofgactinorhodin
AT hindcharlotte revisitingunexploitedantibioticsinsearchofnewantibacterialdrugcandidatesthecaseofgactinorhodin
AT wandmatthewe revisitingunexploitedantibioticsinsearchofnewantibacterialdrugcandidatesthecaseofgactinorhodin
AT randallchristopherp revisitingunexploitedantibioticsinsearchofnewantibacterialdrugcandidatesthecaseofgactinorhodin
AT suttonjmark revisitingunexploitedantibioticsinsearchofnewantibacterialdrugcandidatesthecaseofgactinorhodin
AT seipkeryanf revisitingunexploitedantibioticsinsearchofnewantibacterialdrugcandidatesthecaseofgactinorhodin
AT raynerchristopherm revisitingunexploitedantibioticsinsearchofnewantibacterialdrugcandidatesthecaseofgactinorhodin
AT oneillalexj revisitingunexploitedantibioticsinsearchofnewantibacterialdrugcandidatesthecaseofgactinorhodin